BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies
Reuters
Feb 12
BUZZ-<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on plans to test oral obesity drug in late-stage studies
** Shares of obesity drug developer Viking Therapeutics VKTX.O rise 9.4% to $31.24 after hours
** VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year
** "The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations" — VKTX
** Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks
** VKTX was down 12.6% in 2025
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.